


West Virginia Pharmacy Services



Drug Utilization Review

2nd Quarter 2016

Prepared by :



Drug Utilization Review Board Meeting

09/24/2016

Disclaimer: This report is for trending purposes only and is not intended to match other financial reports.

DUR Quarterly Overall Summary Report
 Report Period from 04/01/2016 thru 06/30/2016

Categories	2nd Qtr 2016	2nd Qtr 2015	% Change
Total Paid Amount	\$62,783,383.67	\$116,375,101.65	-46.05
Eligible Members	110,208	265,251	-58.45
Utilizing Eligibles	56,237	167,030	-66.33
Total # Prescriptions	812,469	1,925,201	-57.80
Cost per Utilizing Member	\$1,116.41	\$696.73	60.23
Average # Prescriptions per Utilizer	14	11	27.27
Average Cost per Prescription	\$77.27	\$60.45	27.84
# Generic Prescriptions	697,104	1,677,747	-58.45
% Generic Prescriptions	85	87	-2.30
Total Cost - Generics	\$13,013,357.41	\$30,136,615.08	-56.82
Average Generic Prescription Cost	\$18.67	\$17.96	3.93
Average Days Supply - Generics	26	25	4.00
# Brand Prescriptions	115,365	247,454	-53.38
% Brand Prescriptions	14.00	12.00	16.67
Total Cost - Brand	\$49,770,026.26	\$86,238,486.57	-42.29
Average Brand Prescription Cost	\$431.41	\$348.50	23.79
Average Days Supply - Brand	26	26	0.00
Rebates Collected	\$84,435,296.21	\$80,795,234.72	4.51

Top 25 Therapeutic Classes By Prescription Count

Report Period from 04/01/2016 thru 06/30/2016

Reporting Months (2nd Quarter) 04/01/2016 - 06/30/2016


Rank	Therapeutic Class	Therapeutic Class Code	Prescription Count	% of Total Prescription Count	Amount Paid
1	ANTICONVULSANTS	H4B	68,065	7.60	\$4,037,263.60
2	PROTON-PUMP INHIBITORS	D4J	39,470	4.40	\$1,954,815.11
3	ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	M4D	32,678	3.70	\$933,321.78
4	ANTIHISTAMINES - 2ND GENERATION	Z2Q	29,940	3.40	\$207,593.40
5	SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	H2S	29,005	3.30	\$259,104.26
6	ANTI-ANXIETY DRUGS	H2F	25,123	2.80	\$210,177.68
7	NARCOTIC ANALGESIC & NON-SALICYLATE ANALGESIC COMB	H3U	24,296	2.70	\$543,040.96
8	BETA-ADRENERGIC AGENTS, INHALED, SHORT ACTING	B6W	23,250	2.60	\$1,199,556.17
9	NSAIDS, CYCLOOXYGENASE INHIBITOR - TYPE ANALGESICS	S2B	22,436	2.50	\$252,660.19
10	BETA-ADRENERGIC BLOCKING AGENTS	J7C	21,845	2.50	\$302,750.18
11	VITAMIN D PREPARATIONS	C6D	20,175	2.30	\$132,705.85
12	ANTIHYPERTENSIVES, ACE INHIBITORS	A4D	19,973	2.20	\$145,309.15
13	ANTIPSYCHOTIC, ATYPICAL, DOPAMINE, SEROTONIN ANTAGNIST	H7T	19,596	2.20	\$2,791,220.38
14	THYROID HORMONES	P3A	16,654	1.90	\$268,740.03
15	SKELETAL MUSCLE RELAXANTS	H6H	15,826	1.80	\$222,655.99
16	LEUKOTRIENE RECEPTOR ANTAGONISTS	Z4B	14,152	1.60	\$191,785.56
17	ANTIHYPERGLYCEMIC, BIGUANIDE TYPE	C4L	14,108	1.60	\$233,362.80
18	ANTIHISTAMINES - 1ST GENERATION	Z2P	13,762	1.50	\$162,718.92
19	INSULINS	C4G	13,650	1.50	\$7,149,275.29
20	HISTAMINE H2-RECEPTOR INHIBITORS	Z2D	13,290	1.50	\$128,213.31
21	ANALGESICS, NARCOTICS	H3A	13,229	1.50	\$618,416.94
22	CALCIUM CHANNEL BLOCKING AGENTS	A9A	11,663	1.30	\$133,704.28
23	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	H7C	10,943	1.20	\$311,632.12
24	PENICILLINS	W1A	10,898	1.20	\$145,610.60
25	LOOP DIURETICS	R1M	10,770	1.20	\$70,597.96
	Totals:		534,797	60.00	\$22,606,232.51

WV POS Quarterly Drug Class Review Top 12 by Rx Count

Reporting Period From: 04/01/2016 - 06/30/2016

Reporting Months (2nd Quarter): 04/01/2016 - 06/30/2016

Top 12 Therapeutic Classes By Prescription Count



Therapeutic Class	Amount Paid
ANTICONSULSANTS	\$4,037,263.60
PROTON-PUMP INHIBITORS	\$1,954,815.11
ANTHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	\$933,321.78
ANTIHISTAMINES - 2ND GENERATION	\$207,593.40
SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	\$259,104.26
ANTI-ANXIETY DRUGS	\$210,177.68
NARCOTIC ANALGESIC & NON-SALICYLATE ANALGESIC COMB	\$543,040.96
BETA-ADRENERGIC AGENTS, INHALED, SHORT ACTING	\$1,199,556.17
NSAIDS, CYCLOOXYGENASE INHIBITOR - TYPE ANALGESICS	\$252,660.19
BETA-ADRENERGIC BLOCKING AGENTS	\$302,750.18
VITAMIN D PREPARATIONS	\$132,705.85
ANTIHYPERTENSIVES, ACE INHIBITORS	\$145,309.15

Top 25 Therapeutic Classes by Amount Paid

Report Period from 04/01/2016 thru 06/30/2016

Reporting Months (2nd Quarter): 4/1/2016-06/30/2016


Rank	Therapeutic Class	Therapeutic Class Codes	Amount Paid	% of Total Amount Paid	Prescription Count
1	INSULINS	C4G	\$7,149,275.29	10.70	13,650
2	ANTICONVULSANTS	H4B	\$4,037,263.60	6.10	68,065
3	BETA-ADRENERGIC AND GLUCOCORTICOID COMBO, INHALED	B63	\$3,175,189.02	4.80	10,387
4	ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED	H7X	\$2,854,064.42	4.30	3,272
5	ANTIPSYCHOTIC, ATYPICAL, DOPAMINE, SEROTONIN ANTAGONIST	H7T	\$2,791,220.38	4.20	19,596
6	PROTON-PUMP INHIBITORS	D4J	\$1,954,815.11	2.90	39,470
7	ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	S2J	\$1,828,893.21	2.70	455
8	ANTICHOLINERGICS, ORALLY INHALED LONG ACTING	B61	\$1,822,100.65	2.70	5,511
9	ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	J5B	\$1,664,185.67	2.50	9,126
10	HEP C VIRUS-NS5B POLYMERASE AND NS5A INHIB. COMBO.	W0B	\$1,542,368.00	2.30	62
11	TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NARCOLEPSY	H2V	\$1,472,681.57	2.20	8,377
12	AGENTS TO TREAT MULTIPLE SCLEROSIS	H0E	\$1,468,049.08	2.20	263
13	ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	V1Q	\$1,359,514.75	2.00	142
14	BETA-ADRENERGIC AGENTS, INHALED, SHORT ACTING	B6W	\$1,199,556.17	1.80	23,250
15	ANTIHYPERLIPIDEMIC - HMG COA REDUCTASE INHIBITORS	M4D	\$933,321.78	1.40	32,678
16	ANTIHYPERGLYCEMIC, DPP-4 INHIBITORS	C4J	\$820,728.44	1.20	2,353
17	GROWTH HORMONES	P1A	\$805,436.17	1.20	258
18	CYSTIC FIBROSIS-CFTR POTENTIATOR & CORRECTOR COMB.	B0F	\$772,413.90	1.20	40
19	LIPOTROPICS	M4E	\$711,736.96	1.10	8,139
20	BLOOD SUGAR DIAGNOSTICS	M4A	\$647,895.94	1.00	10,109
21	TX FOR ATTENTION DEFICIT-HYPERACT.(ADHD), NRI-TYPE	H7Y	\$638,051.25	1.00	1,777
22	ANALGESICS, NARCOTICS	H3A	\$618,416.94	0.90	13,229
23	NARCOTIC WITHDRAWAL THERAPY AGENTS	H3W	\$549,241.92	0.80	4,025
24	NARCOTIC ANALGESIC & NON-SALICYLATE ANALGESIC COMB	H3U	\$543,040.96	0.80	24,296
25	BETA-ADRENERGIC AND ANTICHOLINERGIC COMBO, INHALED	B62	\$509,225.41	0.80	2,527
Totals:			\$41,868,686.59	62.80	301,057

Top 12 Therapeutic Classes by Amount Paid

Reporting Months 2nd Quarter: 4/1/2016-06/30/2016

Reporting Months (2nd Quarter): 4/1/2016-06/30/2016

Top 12 Therapeutic Classes by Amount Paid




Prescriptions

INSULINS	13,650
ANTICONVULSANTS	68,065
BETA-ADRENERGIC AND GLUCOCORTICOID COMBO, INHALED	10,387
ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED	3,272
ANTIPSYCHOTIC, ATYPICAL, DOPAMINE, SEROTONIN ANTAGNIST	19,596
PROTON-PUMP INHIBITORS	39,470
ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	455
ANTICHOLINERGICS, ORALLY INHALED LONG ACTING	5,511
ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	9,126
HEP C VIRUS-NS5B POLYMERASE AND NS5A INHIB. COMBO.	62
TX FOR ATTENTION DEFICIT-HYPERACT(ADHD)/NARCOLEPSY	8,377
AGENTS TO TREAT MULTIPLE SCLEROSIS	263

Pharmacy Generic Utilization Summary by Amount Paid

Reporting Month 2nd Quarter: 4/1/2016-06/30/2016

Reporting Months (2nd Quarter): 4/1/2016-06/30/2016



BNG = Brand With No Generic Available


BWG = Brand Dispensed when Generic Available

GEN = Generic

Pharmacy Generic Utilization Summary By Number Of Prescriptions

Report Period from 04/01/2016 thru 06/30/2016

Reporting Months (2nd Quarter): 4/1/2016-06/30/2016




BNG = Brand With no Generic Available BWG = Brand Dispensed when Generic Available
"GEN = Generic"

Pharmacy DUR Savings - QUARTERLY
 Report Period from 04/01/2016 thru 06/30/2016

Reporting Months (2nd Quarter) : 4/1/2016 - 6/30/2016

DUR SAVINGS



Code	Description	Amount Saved	% of Savings
DD	Drug-Drug Interactions	\$195,847.13	2.00
ER	Early Refill	\$6,425,056.60	57.00
HD	High Dose	\$531,912.24	5.00
ID	Ingredient Duplication	\$405,287.58	4.00
LR	Late Refill	\$0.00	0.00
PG	Pregnancy Precaution	\$21,498.12	0.00
TD	Therapeutic Duplication	\$3,684,600.41	33.00
Totals:		\$11,264,202.08	100.00